These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7288175)

  • 1. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus.
    Masurel N; Ophof P; de Jong P
    J Hyg (Lond); 1981 Oct; 87(2):201-9. PubMed ID: 7288175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults.
    Frank AL; Webster RG; Glezen WP; Cate TR
    J Med Virol; 1981; 7(2):135-42. PubMed ID: 7264612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):361-70. PubMed ID: 6863910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):351-9. PubMed ID: 6863909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
    Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines.
    Brandriss MW; Betts RF; Mathur U; Douglas RG
    Am Rev Respir Dis; 1981 Dec; 124(6):681-4. PubMed ID: 7316272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine in unprimed children: improved immunogenicity with few reactions following one high dose of split-product vaccine.
    Gross PA; Ennis FA; Noble GR; Gaerlan PF; Davis WJ; Denning CE
    J Pediatr; 1980 Jul; 97(1):56-60. PubMed ID: 7381649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977-1979.
    Foy HM; Cooney MK; Taylor J; Allan I; Chuang TY; Blumhagen J; Fox JP
    J Infect Dis; 1980 Aug; 142(2):139-44. PubMed ID: 7410896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults].
    Profeta ML; Bigatello A; Vacchini V; Bramati L; Ferrante P
    Boll Ist Sieroter Milan; 1980 Jan; 58(6):457-74. PubMed ID: 6778485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgM and IgG antibody responses following immunization of children and adults with influenza A/NJ/76 vaccines.
    Boyer KM; Cherry JD; Noble GR
    Dev Biol Stand; 1977 Jun 1-3; 39():303-8. PubMed ID: 604113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.